FDA Approves Once-a-Month Dose of Actonel
April 25, 2008
The Alliance for Better Bone Health, a collaboration between Procter & Gamble Pharmaceuticals and Sanofi-Aventis US, has announced that FDA has approved a new once-a-month dose of Actonel tablets for the treatment and prevention of postmenopausal osteoporosis.
Actonel is approved to reduce the risk of fractures in postmenopausal women with osteoporosis.
The FDA approval of the once-a-month dose is based on a study comparing Actonel 150mg once monthly to Actonel 5mg daily. Similar increases in bone mineral density (BMD) were seen among patients under once-a-month or daily dosing regimens.